Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e3830f35387a1c32061dea3ee310851 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 |
filingDate |
2014-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d400232fb7950bf6194b778d1c6a95f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fae2606b97cdd810a54dcdc6a62846da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b31d4c05e1c2d96577e8b273fb3a026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9be1004f69a178b1deae31523fccf6d6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6625eb41f161740aaa73c5b8958bbdf |
publicationDate |
2020-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3756669-A1 |
titleOfInvention |
Compositions for use for treating cutaneous t cell lymphoma |
abstract |
The present invention provides methods for treating a subject with cutaneous T cell lymphoma (CTCL). In one embodiment, a subject is administered an effective amount effective of an IRM compound wherein at least one symptom or clinical sign of CTCL is ameliorated. The present invention further includes a method of increasing a cell-mediated immune response of a cell population that includes cells affected by CTCL. In one embodiment, an effective amount of the cell population is contacted with an IRM compound wherein at least one cell-mediated immune activity of the cell population is increased. |
priorityDate |
2013-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |